Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-HCM
KCT0012776Phase 4Not yet recruiting
- Sponsor
- HK inno.N Corporation
- Start
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Change from baseline in peak oxygen consumption. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on KCT0012776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012776.